{"filing":{"accession_number":"0001628280-26-048574","cik":"0000910329","ticker":"MED","company_name":"MEDIFAST INC","form":"8-K","filing_date":"2026-07-17","report_date":null,"primary_document":"med-20260717.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/910329/000162828026048574/med-20260717.htm"},"events":[{"id":18595,"run_id":16716,"accession_number":"0001628280-26-048574","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Medifast announced a major rebranding of its OPTAVIA subsidiary to Trilivy, a comprehensive metabolic health system, accompanied by new product formulations and a strategic shift from weight loss to metabolic health. This represents a significant operational and strategic transformation that would affect investor assessment of the company's market positioning and product strategy, but does not fit the specific categories of M\u0026A activity, earnings release, or other named event types. The disclosure emphasizes this as a \"major corporate transformation\" and \"new era,\" making it material to investors evaluating the company's direction and competitive positioning.","company_name":"MEDIFAST INC","ticker":"MED","filing_date":"2026-07-17","form":"8-K","submitted_at":null,"items":[{"id":17451,"accession_number":"0001628280-26-048574","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Medifast announced a major rebranding of its OPTAVIA subsidiary to Trilivy, a comprehensive metabolic health system, accompanied by new product formulations and a strategic shift from weight loss to metabolic health. This represents a significant operational and strategic transformation that would affect investor assessment of the company's market positioning and product strategy, but does not fit the specific categories of M\u0026A activity, earnings release, or other named event types. The disclosure emphasizes this as a \"major corporate transformation\" and \"new era,\" making it material to investors evaluating the company's direction and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T12:34:40.550365+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17451,"accession_number":"0001628280-26-048574","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Medifast announced a major rebranding of its OPTAVIA subsidiary to Trilivy, a comprehensive metabolic health system, accompanied by new product formulations and a strategic shift from weight loss to metabolic health. This represents a significant operational and strategic transformation that would affect investor assessment of the company's market positioning and product strategy, but does not fit the specific categories of M\u0026A activity, earnings release, or other named event types. The disclosure emphasizes this as a \"major corporate transformation\" and \"new era,\" making it material to investors evaluating the company's direction and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T12:34:40.550365+00:00","company_name":"MEDIFAST INC","ticker":"MED","filing_date":"2026-07-17"}]}